UPSTAZA

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, United Kingdom

Active ingredients

The drug UPSTAZA contains one active pharmaceutical ingredient (API):

1 Eladocagene exuparvovec UNII S51J6N56M7 - ELADOCAGENE EXUPARVOVEC

Eladocagene exuparvovec is a gene therapy based on recombinant AAV2 vector containing the human cDNA for the DDC gene. After infusion into the putamen, the product results in the expression of the AADC enzyme and subsequent production of dopamine, and consequently, development of motor function in treated AADC-deficient patients. Read about Eladocagene exuparvovec

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
UPSTAZA Solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A16AB26		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB26

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3046722
Country: FR	Base de données publique des médicaments	Identifier(s): 61876862
Country: IT	Agenzia del Farmaco	Identifier(s): 050223015
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095124